- Home
- SGU vs IMTX Comparison
SGU vs IMTX Comparison
Compare SGU & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- IMTX
- Stock Information
- Founded
- SGU 1995
- IMTX N/A
- Country
- SGU United States
- IMTX Germany
- Employees
- SGU N/A
- IMTX N/A
- Industry
- SGU Other Specialty Stores
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGU Consumer Discretionary
- IMTX Health Care
- Exchange
- SGU Nasdaq
- IMTX Nasdaq
- Market Cap
- SGU 447.6M
- IMTX 514.2M
- IPO Year
- SGU 1995
- IMTX N/A
- Fundamental
- Price
- SGU $12.75
- IMTX $4.26
- Analyst Decision
- SGU
- IMTX Strong Buy
- Analyst Count
- SGU 0
- IMTX 4
- Target Price
- SGU N/A
- IMTX $16.67
- AVG Volume (30 Days)
- SGU 38.9K
- IMTX 849.5K
- Earning Date
- SGU 04-30-2025
- IMTX 05-13-2025
- Dividend Yield
- SGU 5.36%
- IMTX N/A
- EPS Growth
- SGU 69.46
- IMTX N/A
- EPS
- SGU 1.36
- IMTX 0.14
- Revenue
- SGU $1,726,066,000.00
- IMTX $161,336,577.00
- Revenue This Year
- SGU N/A
- IMTX N/A
- Revenue Next Year
- SGU N/A
- IMTX $18.80
- P/E Ratio
- SGU $9.36
- IMTX $29.39
- Revenue Growth
- SGU N/A
- IMTX 188.60
- 52 Week Low
- SGU $9.64
- IMTX $3.30
- 52 Week High
- SGU $13.75
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- SGU 43.49
- IMTX 48.54
- Support Level
- SGU $12.44
- IMTX $4.03
- Resistance Level
- SGU $13.19
- IMTX $4.48
- Average True Range (ATR)
- SGU 0.44
- IMTX 0.39
- MACD
- SGU -0.05
- IMTX 0.05
- Stochastic Oscillator
- SGU 36.94
- IMTX 75.00
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.